Infinity Pharmaceuticals Inc.  

(Public, NASDAQ:INFI)   Watch this stock  
Find more results for INFI
10.50
0.00 (0.00%)
Apr 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 8.91 - 44.50
Open     -
Vol / Avg. 200.00/689,962.00
Mkt cap 506.95M
P/E     -
Div/yield     -
EPS -2.64
Shares 48.28M
Beta 0.82
Inst. own 99%
Jun 9, 2014
Infinity Pharmaceuticals, Inc. Annual Shareholder Meeting (Estimated) Add to calendar
May 5, 2014
Q1 2014 Infinity Pharmaceuticals, Inc. Earnings Release (Estimated) Add to calendar
Mar 10, 2014
Infinity Pharmaceuticals, Inc. at Bernstein's Emerging Biotech Conference
Mar 5, 2014
Infinity Pharmaceuticals, Inc. at Cowen Health Care Conference - Webcast
Feb 26, 2014
Infinity Pharmaceuticals, Inc. at RBC Capital Markets Healthcare Conference - Webcast
Feb 26, 2014
Infinity Pharmaceuticals, Inc. at Citi Global Healthcare Conference
Feb 25, 2014
Q4 2013 Infinity Pharmaceuticals, Inc. Earnings Release
Feb 25, 2014
Q4 2013 Infinity Pharmaceuticals, Inc. Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -53.74% -44.77%
Return on average equity -61.21% -49.57%
Employees 151 -
CDP Score - -

Address

780 Memorial Drive
CAMBRIDGE, MA 02139
United States - Map
+1-617-4531000 (Phone)
+1-617-4531001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Infinity Pharmaceuticals, Inc. (IPI) is a drug discovery and development company. The Company's lead product is a potent, oral inhibitor of Class I PI3K-delta and PI3K-gamma, which the Company is investigating in both hematologic malignancies and inflammatory diseases.Its retaspimycin hydrochloride (HCl), is a potent and selective inhibitor of heat shock protein 90 (Hsp90). The phosphoinositide-3-kinases (PI3Ks) are key cellular signaling proteins that act as a central node for relaying signals from cell surface receptors to downstream biochemical events. The Company�s lead development candidate in this program is IPI-145 a potent, oral inhibitor of Class I PI3K-delta,gamma for which clinical trials are conducted form both hematologic malignancies and inflammatory diseases. Hematologic malignancies are cancers of the blood or bone marrow and include leukemia and lymphoma, such as chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, and non-Hodgkin lymphoma (NHL).

Officers and directors

Adelene Q. Perkins Chairman of the Board, President, Chief Executive Officer
Age: 53
Bio & Compensation  - Reuters
Lawrence E. Bloch M.D., J.D. Chief Financial Officer, Executive Vice President, Chief Business Officer
Age: 49
Bio & Compensation  - Reuters
Julian Adams Ph.D. President - Research & Development
Age: 58
Bio & Compensation  - Reuters
Vito J. Palombella Ph.D. Chief Scientific Officer
Age: 50
Bio & Compensation  - Reuters
Winselow S. Tucker Jr. Vice President - Marketing
Age: 45
Bio & Compensation  - Reuters
Joshua D. Hamermesh Vice President - Business and Corporate Development
Age: 41
Bio & Compensation  - Reuters
David A. Roth M.D. Chief Medical Officer
Bio & Compensation  - Reuters
Anthony B. Evnin Ph.D. Lead Outside Independent Director
Age: 72
Bio & Compensation  - Reuters
Jose Baselga M.D., Ph.D. Independent Director
Bio & Compensation  - Reuters
Jeffrey Berkowitz Independent Director
Bio & Compensation  - Reuters